AGR2 expression in ovarian tumours: A potential biomarker for endometrioid and mucinous differentiation

Pathology

Volumn 45, Issue 1, 2013, Pages 49-54

  Armes, Jane E ^a   Davies, Claire M ^a   Wallace, Sarah ^a   Taheri, Touraj ^a,b   Perrin, Lewis C ^a   Autelitano, Dominic J ^c  

^a MATER HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c HealthLinx Ltd   (Australia)

Author keywords

AGR2; Immunohistochemistry; Ovarian cancer; Ovarian tumours; Tissue microarrays

Indexed keywords

EID: 84873846187     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835bd561     Document Type: Article

References (41)

1. Australian Institute of Health and Welfare (AIHW). Cancer in Australia, 2010: An Overview. Canberra: AIHW, 2010.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007, CA. Cancer J Clin 2007; 57: 43-66.
3. Young R. Gynecological malignancies In: Fauci AS, Braunwald E, Kasper DL, et al., editors. Harrison's Principles of Internal Medicine. New York: McGraw Medical, 2008.
4. Edge S, Byrd D, Compton C, et al. AJCC Cancer Staging Manual. Chicago: Springer, 2010; 422.
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2011; 127: 2893-917.
6. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-8.
7. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008; 27: 151-60.
8. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011; 43: 420-32.
9. Russell SE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004; 203: 617-9.
10. Singer G, Kurman RJ, ChangHW, Cho SK, Shih Ie M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160: 1223-8.
11. Singer G, Shih Ie M, Truskinovsky A, Umudum H, Kurman RJ. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol 2003; 22: 37-41.
12. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29: 218-24.
13. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004; 64: 6915-8.
14. Sieben NL, Macropoulos P, Roemen GM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004; 202: 336-40.
15. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16: 267-82.
16. Irving JA, Clement PB. Nonneoplastic lesions of the ovary. In: Kurman RJ, Ellenson LH, Ronnett BM. Blaustein's Pathology of the Female Genital Tract. 6th ed. New York: Springer, 2011; 590.
17. Armes JE, Lourie R, de Silva M, et al. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 2005; 24: 363-8.
18. Aberger F, Weidinger G, Grunz H, Richter K. Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mech Dev 1998; 72: 115-30.
19. Edgell TA, Barraclough DL, Rajic A, et al. Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin Sci (Lond) 2010; 118: 717-25.
20. Park K, Chung YJ, So H, et al. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med 2011; 43: 91-100.
21. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000; 19: 7-15.
22. Kumar B, De Silva M, Venter DJ, Armes JE. Tissue microarrays: a practical guide. Pathology 2004; 36: 295-300.
23. Barraclough DL, Platt-Higgins A, de Silva Rudland S, et al. The metastasisassociated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol 2009; 175: 1848-57.
24. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-6.
25. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999; 59: 2011-7.
26. Armes JE, Bowlay G, Lourie R, Venter DJ, Price G. Differential diagnosis of serous papillary carcinoma of the gynaecological tract and basal breast carcinoma: an immunohistochemical approach. Pathology 2010; 42: 534-9.
27. Aldovini D, Demichelis F, Doglioni C, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer 2006; 119: 1920-6.
28. Liu CL, Montgomery KD, Natkunam Y, et al. TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod Pathol 2005; 18: 1641-8.
29. Pinke DE, Kalloger SE, Francetic T, Huntsman DG, Lee JM. The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol Oncol 2008; 108: 561-8.
30. Kurman RJ, McConnell TG. Precursors of endometrial and ovarian carcinoma. Virchows Archiv 2010; 456: 1-12.
31. Kobel M, Reuss A, Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010; 222: 191-8.
32. Seidman JD, Cho KR. Surface epithelial tumors of the ovary. In: Kurman RJ, Ellenson LH, Ronnett BM. Blaustein's Pathology of the Female Genital Tract. 6th ed. New York: Springer, 2011; 683.
33. Tan DS, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 2007; 60: 355-60.
34. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-43.
35. Clement PB. Histology of the ovary. In: Sternberg SS, editor. Histology for Pathologists. Philadelphia: Lippincott-Raven, 1997; 932.
36. Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008; 68: 492-7.
37. Ramachandran V, Arumugam T,Wang H, Logsdon CD. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 2008; 68: 7811-8.
38. Pohler E, Craig AL, Cotton J, et al. The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics 2004; 3: 534-47.
39. Park SW, Zhen G, Verhaeghe C, et al. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci USA 2009; 106: 6950-5.
40. Fletcher GC, Patel S, Tyson K, et al. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptorpositive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer 2003; 88: 579-85.
41. King ER, Tung CS, Tsang YT, et al. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol 2011; 35: 904-12.